Harmony Biosciences

Harmony Biosciences

Biopharmaceutical company and a member of the Paragon Biosciences corporate family. Learn more

Launch date
Employees
Market cap
$2.2b
Enterprise valuation
$2.0b (Public information from Sep 2024)
Upper Merion Township Pennsylvania (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues160m305m438m582m710m843m997m
% growth2565 %91 %43 %33 %22 %19 %18 %
EBITDA13.9m87.5m120m231m185m310m394m
% EBITDA margin9 %29 %27 %40 %26 %37 %40 %
Profit(36.9m)34.6m181m129m137m229m305m
% profit margin(23 %)11 %41 %22 %19 %27 %31 %
EV / revenue12.7x8.0x7.3x3.0x2.5x2.0x1.3x
EV / EBITDA145.3x28.0x26.7x7.6x9.5x5.3x3.3x
R&D budget19.4m30.4m70.9m76.1m---
R&D % of revenue12 %10 %16 %13 %---
  • Edit
DateInvestorsAmountRound
-

N/A

-
*

$270m

Growth Equity VC

$200m

Debt

$50.0m

Series C

$200m

Debt
N/A

$128m

Valuation: $1.5b

250.2x EV/LTM Revenues

-10.5x EV/LTM EBITDA

IPO

$300m

Post IPO Debt

$30.0m

Post IPO Equity
*

$185m

Post IPO Debt
*

N/A

Post IPO Equity
Total Funding$320m

Recent News about Harmony Biosciences

Edit
More about Harmony Biosciencesinfo icon
Edit

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. The company operates in the healthcare sector, specifically targeting conditions that have limited treatment options. Harmony Biosciences serves patients, healthcare providers, and the broader medical community by bringing breakthrough science within reach. The business model revolves around the research, development, and commercialization of novel medications, generating revenue through the sale of these specialized therapies. The company invests heavily in scientific research to identify new clinical possibilities and advance the treatment landscape for rare neurological disorders.

Keywords: biopharmaceutical, rare diseases, neurological, innovative therapies, commercialization, healthcare, research, development, novel medications, breakthrough science.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Harmony Biosciences

Edit
Zynerba Pharmaceuticals (Formerly AllTranz)
ACQUISITION by Harmony Biosciences Aug 2023
Epygenix
ACQUISITION by Harmony Biosciences Apr 2024